SBI Securities
LCTX icon

SBI Securities’s Lineage Cell Therapeutics LCTX Stock Holding History

SBI Securities’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.75K Buy
7,445
+310
+4% +$428 ﹤0.01% 1852
2026
Q1 		$11.3K Sell
7,135
-325
-4% -$548 ﹤0.01% 1677
2025
Q4 		$12.5K Sell
7,460
-412
-5% -$713 ﹤0.01% 1628
2025
Q3 		$13.3K Sell
7,872
-409
-5% -$484 ﹤0.01% 1629
2025
Q2 		$7.51K Sell
8,281
-320
-4% -$190 ﹤0.01% 1820
2025
Q1 		$3.88K Buy
8,601
+1,900
+28% +$1.11K ﹤0.01% 2000
2024
Q4 		$3.37K Buy
+6,701
New +$4.92K ﹤0.01% 2078

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SBI Securities's LCTX Position: Q2 2026 in Review

SBI Securities increased its Lineage Cell Therapeutics (LCTX) stake by 4.3% in Q2 2026, buying an estimated $428 and bringing the position to 7,445 shares worth $9.75K. The position accounts for ﹤0.01% of the portfolio, ranked #1852.

SBI Securities first reported a position in LCTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $13.3K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • SBI Securities held 7,445 shares of Lineage Cell Therapeutics worth $9.75K as of Q2 2026.
  • SBI Securities bought 310 Lineage Cell Therapeutics shares in Q2 2026, an estimated $428.
  • Lineage Cell Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1852 holding.
  • SBI Securities first reported a position in Lineage Cell Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Lineage Cell Therapeutics position peaked at $13.3K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.